Symbol not found

:CELG   00:00AM GMT
0.00
0.00 (0.00%)
StockTwits Share  Twitter Share  Facebook Share

The Largest Drug Pipelines in Biotech Will Move the Market


Biotech Pipelines

Written by Ophir Gottlieb, 12-15-2015


PREFACE
New drug candidates are the life blood of biotech stocks, from the enormously profitable to the barely breathing. Here are the companies with the largest pipelines of potential drug candidates that we must be watching.


STORY
Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase I: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.

Phase II: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.

Phase III: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely. After these trials companies move to the formal step called New Drug Application (NDA). In this step a drug sponsor takes the results to ask that the FDA to consider approving a new drug for marketing in the United States.

We write one story a day using visuals to break critical news with chart data that to this point has been kept away from the general public. Join Us: Get Our (Free) News Alerts Once a Day.

Here are the largest biotech companies ranked by the number of Phase III trials they have in progress.


Mega Cap Pharmaceutical Companies Were Removed


Do you thrive on seeing data that goes way beyond headlines and turns you into an expert? Try CML Pro. No credit Card. No Payment Info. Just the Power.

We note that Amgen and Celgene are both tied with 12. Gilead and Biogen round out the "big four" biotechs with 4 and 7, respectively.

But of course, it's not just Phase III that matters, as Phase II data can easilymove a stock as abruptly as a later stage III trial. Here is that same group of large cap biotechs ranked by Phase II trials.


Mega Cap Pharmaceutical Companies Were Removed


Do you thrive on seeing data that goes way beyond headlines and turns you into an expert? Try CML Pro. No credit Card. No Payment Info. Just the Power.

It's interesting to note that Celgene has both the most Phase III trials and the most Phase II trials. I have highlighted in yellow biotechs other three that comprise the "big four."

Do you enjoy using visualizations to understand what's really going on in a company? Get Our (Free) News Alerts Twice a Week.

WHY THIS MATTERS
The top analysts, asset managers and hedge fund managers are keenly aware of the data coming out in biotechs that will move markets. It's the most critical data for many biotechs and if we're not using this data, then we're trading against people that simply have more information then we do. That is a wealth losing strategy.

Data like this, until now, has been kept away from retail investors. The information asymmetry that exists between pros and non-pros has transferred massive wealth to the top 1% from the rest of us. That information asymmetry is no longer acceptable to us.

The full stories on Celgene, Gilead, Amgen, Biogen, Alexion, Jazz Pharma, Regeneron and many others are available in the biotech corner in CML Pro.

This is just one of the fantastic reports CML Pro members get. For a (very) limited time we are offering CML Pro at a 90% discount for $10/mo. with a lifetime guaranteed rate. Join Us: Get the most advanced premium research delivered to your inbox along with access to visual tools and data that until now has only been made available to the top 1%.